Spree Pharma

Spree Therapeutics is a Swiss biotechnology company pioneering the development of circular RNA (circRNA) as a novel therapeutic modality. The company's proprietary Spree-circ platform is designed to overcome the stability and duration-of-effect limitations of traditional linear mRNA, enabling the sustained expression of therapeutic proteins in vivo. Spree is primarily focused on protein replacement therapies for rare and metabolic diseases, where long-lasting protein production can significantly improve patient outcomes. Headquartered in Basel, the company is advancing a pipeline of pre-clinical candidates for both systemic and localized delivery. Spree Therapeutics is backed by specialized life science investors and aims to establish circRNA as a cornerstone of next-generation genetic medicine.